Mike Rafii’s proposal to develop a clinical trials network for conducting AD clinical trials in the Down syndrome population has been funded. The Alzheimer’s Clinical Trial Consortium for Down Syndrome (ACTC-DS) will leverage the experience and expertise of the ACTC, as well as the NIH-funded Alzheimer’s Biomarker Consortium for Down Syndrome (ABC-DS) groups to build a trial-ready cohort of adults with DS and then design and conduct a clinical trial in this cohort. ACTC-DS will serve as a platform for bringing the latest and most innovative AD therapies to the DS population.
Footer
